Diagnostic Photonics, a Serra Capital I and II portfolio company, was featured by R&D Magazine on September 16. Diagnostic Photonics has developed a hand-held probe based on a technology called optical coherence tomography, which is used for surgical guidance and the real-time assessment of breast cancer tumor margin.
The tool which uses light to make sure surgeons removing cancerous tumors “got it all” was found to correlate well with traditional pathologists’ diagnoses in a clinical study, showing that the tool could soon enable reliable, real-time guidance for surgeons.
The interdisciplinary research team led by Stephen Boppart, a Univ. of Illinois professor, performed the study on 35 patients with breast cancers at the Carle Foundation Hospital in Urbana, Ill. The results appear in the journal Cancer Research.